A reversal in the vascularity of metastatic liver tumors from colorectal cancer after the cessation of chemotherapy plus bevacizumab: Contrast-enhanced ultrasonography and histological examination

Chemotherapy Before Liver Resection of Colorectal Metastases

(2011) Kuno Lehmann et al.   ANNALS OF SURGERY

Impact of preoperative targeted therapy on postoperative complications after resection of colorectal liver metastases

(2011) Hannes P. Neeff et al.   INTERNATIONAL JOURNAL OF COLORECTAL DISEASE

Liver Resection Remains a Safe Procedure After Neoadjuvant Chemotherapy Including Bevacizumab

(2010) Dietmar Tamandl et al.   ANNALS OF SURGERY

Sinusoidal obstruction syndrome and nodular regenerative hyperplasia are frequent oxaliplatin-associated liver lesions and partially prevented by bevacizumab in patients with hepatic colorectal metastasis

(2010) Laura Rubbia-Brandt et al.   HISTOPATHOLOGY

Reversibility of capillary density after discontinuation of bevacizumab treatment

(2009) N. Steeghs et al.   ANNALS OF ONCOLOGY

Bevacizumab protects against sinusoidal obstruction syndrome and does not increase response rate in neoadjuvant XELOX/FOLFOX therapy of colorectal cancer liver metastases

(2009) M. Klinger et al.   EJSO

Association of Computed Tomography Morphologic Criteria With Pathologic Response and Survival in Patients Treated With Bevacizumab for Colorectal Liver Metastases

(2009) Yun Shin Chun   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Impact of Preoperative Bevacizumab on Complications After Resection of Colorectal Liver Metastases: Case-Matched Control Study

(2009) Mahfud Mahfud et al.   WORLD JOURNAL OF SURGERY

Complete Pathologic Response After Preoperative Chemotherapy for Colorectal Liver Metastases: Myth or Reality?

(2008) René Adam et al.   JOURNAL OF CLINICAL ONCOLOGY

Preoperative Bevacizumab Does Not Significantly Increase Postoperative Complication Rates in Patients Undergoing Hepatic Surgery for Colorectal Cancer Liver Metastases

(2008) Susan B. Kesmodel et al.   JOURNAL OF CLINICAL ONCOLOGY

Pathologic Response to Preoperative Chemotherapy: A New Outcome End Point After Resection of Hepatic Colorectal Metastases

(2008) Dan G. Blazer et al.   JOURNAL OF CLINICAL ONCOLOGY

Bevacizumab, Capecitabine, and Oxaliplatin As Neoadjuvant Therapy for Patients With Potentially Curable Metastatic Colorectal Cancer

(2008) Brigit Gruenberger et al.   JOURNAL OF CLINICAL ONCOLOGY

Bevacizumab in Combination With Oxaliplatin-Based Chemotherapy As First-Line Therapy in Metastatic Colorectal Cancer: A Randomized Phase III Study

(2008) Leonard B. Saltz et al.   JOURNAL OF CLINICAL ONCOLOGY

Targeted therapies and surgical issues in gastrointestinal cancers

(2008) Alexander A. Parikh et al.   Targeted Oncology

Addition of Bevacizumab to Irinotecan- and Oxaliplatin-Based Preoperative Chemotherapy Regimens Does Not Increase Morbidity after Resection of Colorectal Liver Metastases

(2007) Srinevas K. Reddy et al.   JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS